REFERENCES
- Green GA, Carey RN, Westgard JO, Carten T, Shablesky L, Achord D, et al. Quality control for qualitative assays: quantitative QC procedure designed to assure analytical quality required for an ELISA of hepatitis B surface antigen. Clin Chem 1997; 43: 1618–21.
- Courouce A-M, Bouchardeau F, Girault A, Le Marrec N. Significance of N53 and N55 antigens in screening for HCV antibody. Lancet 1994; 343: 853 — 4.
- Vernelen K, Claeys H, Verhaert H, Volckaerts A, Vermylen C. Significance of N53 and N55 antigens in screening for HCV antibody. Lancet 1994; 343: 853.
- Bondarenko IG, Bogovskaya TY, Vronskiy YD, Savinova IN, Mamedova EM, Sedunova YA. Internal quality control of five Russian ELISA test systems for the detection of antibodies to hepatitis C virus. In: Proceedings of the XVI International Congress of Clinical Chemistry, London, 1996: 524.
- Leon P, Lopez JA, Elola C, Domingo CJ, Ecchevarria JM. Are synthetic peptides sensitive enough for screening anti-hepatitis C virus at blood banks? Vox Sang 1994; 67: 83–4.
- Garcia-Samanego J, Soriano V, Silva E, Enriques A, Munos F, Gonzalez-Lahoz J, et al. Significance of HCV RIBA-2 indeterminate results in high-risk individuals: assessment by a new third-generation RIBA assay and PCR. Vox Sang 1994; 66: 148–9.
- Thorn RM, Braman V, Stella M, Yi A. Assess-ment of HIV-1 screening test sensitivities using serially diluted positive sera can give misleading results. Transfusion 1989; 29: 78–80.
- Newest HCV assay speeds detection [Editorial]. Issues in Hepatitis 1993: 3–4.
- Zhang ZX, Chen M, Sonnenberg A, Weiland 0, Sallberg M. Distinguishing acute from sympto-matic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. J Infect Dis 1995; 171: 1356–9.
- Zhang ZX. Humoral and cellular immune responses to proteins encoded by the hepatitis C virus [Dissertation]. Stockholm: 1997
- Gray JJ, Wreight TG, Friend PJ, Wight DGD, Sundaresan V, Calne RY. Differentiation between specific and non-specific hepatitis C antibodies in chronic liver disease. Lancet 1990; 335: 609–10.
- Alter H. To C or not to C: these are the questions. Blood 1995; 85: 1681–95.
- Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment, and prevention. Report of a meeting of physicians and scientists, Royal Free Hospital and School of Medicine, London. Lancet 1995; 345: 562–6.
- Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89: 3468–72.
- Lesniewski RR, Boardway KM, Casey JM, Desai SM, Devare SG, Leung TK, et al. Hypervariable 5'-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol 1993; 40: 150–6.
- Urushihara A, Sodeyama T, Matsumoto A, Tanaka E. Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection. J Med Virol 1994; 42: 348–56.